explore -WSS

explore

author：explore 2025-09-14 21:59:59 - browse：66262

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： A new study sees potential in DNA sequencing of infants

knowledge

WSS

Is there really a nursing shortage in the U.S.?

STAT Readout: Friday, Oct. 20 biotech updates

Study on Amgen’s bispecific immunotherapy produces positive data

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Readout LOUD podcast: Live from the 2023 STAT Summit

Is there really a nursing shortage in the U.S.?

hotspot

explore

hotspot

Drug repurposing or repositioning? The language matters

Palantir health business leans on meeting customers’ needs

State Dept. review finds Biden bears some blame for Afghanistan failures

Study: Pain burden is higher in Black NFL players than white ones

Trump demands the U.S. pay no more for drugs than other countries … again

Roche drug slashes death risk in early

DIEP, the 'gold standard' of breast reconstruction, is under threat

The problems with dementia villages

Tori Bowie and the unacceptable rates of Black maternal death

Beach reads and more: STAT's 2023 summer book list

hotspot

Merck, Daiichi strike cancer drug pact worth up to $22 billion

FDA clears Verve to begin U.S. study of gene

How the political right came to back psychedelics to treat trauma

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Study: Pain burden is higher in Black NFL players than white ones

ADCs take center stage as promising cancer treatments

Wikipedia

knowledge

explore

Wikipedia